Transcriptome-wide association analysis is a powerful approach to studying the genetic architecture of complex traits. A key component of this approach is to build a model to predict (impute) gene expression levels from genotypes from samples with matched genotypes and expression levels in a specific tissue. However, it is challenging to develop robust and accurate imputation models with limited sample sizes for any single tissue. Here, we first introduce a multi-task learning approach to jointly impute gene expression in 44 human tissues. Compared with single-tissue methods, our approach achieved an average 39% improvement in imputation accuracy and generated effective imputation models for an average 120% (range 13%-339%) more genes in each tissue. We then describe a summary statistic-based
Introduction
Genome-wide association studies (GWASs) have successfully identified numerous single-nucleotide polymorphisms (SNPs) associated with complex human traits and diseases. Despite these successes, significant problems remain in statistical power and biological interpretation of GWAS results [1, 2] . In particular, the complex architecture of linkage disequilibrium (LD) and context-dependent regulatory machinery in the genome hinder our ability to accurately identify causal genes from GWAS, thereby raising challenges in downstream functional validation and therapeutic development. Recently, large-scale consortia, such as the Genotype-Tissue Expression (GTEx) project [3, 4] , have generated matched genotype and expression data for various human tissues. These rich data sets have provided great insights into mechanisms of cross-tissue transcriptional regulation and accelerated discoveries for expression quantitative trait loci (eQTL) [4] [5] [6] [7] . In addition, integrating eQTL information in genetic association analysis has become an effective way to bridge SNPs, genes, and complex traits. Many methods have been developed to co-localize eQTL with loci identified in GWAS to identify causal genes for complex traits [8] [9] [10] [11] [12] [13] . Two recent studies addressed this issue through an innovative approach that is sometimes referred to as transcriptome-wide association analysis. First, based on an externally-trained imputation model, gene expression is imputed using genotype information in GWAS samples. Next, gene-level association is assessed between imputed gene expression and the trait of interest [14, 15] . These methods have become popular in the past two years due to their capability to effectively utilize signals from multiple eQTLs with moderate effects and to reduce the impact of reverse causality in expression-trait association analysis. The applications of these methods have led to novel insights into the genetic basis of many diseases and traits [16] [17] [18] .
Despite these successes, the existing methods have several limitations. First, due to the tissue-dependent nature of transcription regulation, existing methods train separate imputation models for different tissues. This practice ignores similarity in transcription regulation across tissues, thereby limiting the effective sample sizes for tissues that are difficult to acquire. Second, a hypothesis-free search across genes and tissues increases the burden of multiple testing and thus reduces statistical power. Pinpointing a subset of tissues based on prior knowledge may resolve this issue to some extent, but for many complex traits the biologically relevant tissues are either unknown or unavailable. Further, recent reports have shown that eQTL with large effects tend to regulate gene expression in multiple tissues [4] . Genetic correlation analysis has also suggested substantial sharing of local expression regulation across tissues [19] . This would inevitably result in statistically significant associations in tissues irrelevant to the complex trait, a phenomenon that has been extensively discussed recently [20] . Finally, the correlation between eQTL effects across tissues may be partially caused by sample overlap among tissues in the reference dataset, which further complicates the interpretation of association results.
Jointly analyzing data from multiple genetically-correlated tissues has the potential to resolve these issues. It has been recently demonstrated that multi-trait analysis could improve accuracy of genetic risk prediction [21] [22] [23] . Multi-tissue modeling has also been shown to improve the statistical power in eQTL analysis [24] [25] [26] [27] and gene network studies [28] . In this work, we demonstrate that a novel cross-tissue strategy could also improve transcriptome-wide association analysis.
We introduce UTMOST (Unified Test for MOlecular SignaTures), a principled method to perform cross-tissue expression imputation and gene-level association analysis.
We demonstrate its performance through internal and external imputation validation evaluations, numerical simulations, analyses of 50 complex traits, a case-study on low-density lipoprotein cholesterol (LDL-C), and a multi-stage association study for late-onset Alzheimer's disease (LOAD). We show that UTMOST substantially improves expression imputation accuracy in all tissues. For downstream analysis, UTMOST provides a powerful metric that summarizes gene-level associations across tissues and can be extended to integrate multiple molecular phenotypes.
Results

Model overview
5
The UTMOST framework consists of three main stages (Figure 1) . First, for each gene in the genome, we train a cross-tissue expression imputation model using the genotype information and matched expression data from 44 tissues in GTEx. Next, we test associations between the trait of interest and imputed expression in each tissue. Lastly, a joint test is performed for each gene to summarize single-tissue association statistics into a powerful metric that quantifies the overall gene-trait association. Here, we briefly introduce the UTMOST framework. All the mathematical details are discussed in the Methods section. We formulate cross-tissue expression imputation as a penalized multivariate regression problem:
where , , and denote the sample size in the training data, the number of SNPs in the imputation model, and the total number of tissues, respectively. Since only a subset of tissues was collected from each individual, expression data in matrix were incomplete and sample sizes for different tissues were unbalanced. In order to effectively utilize information across tissues while addressing these issues, we estimate by minimizing the squared loss function with a lasso penalty on the columns (within-tissue effects) and a group-lasso penalty on the rows (cross-tissue effects) via the following optimization problem (Methods).
= argmin
where ! , ! , and ! denote the observed expression, genotypes, and sample size of the ith tissue, respectively. Parameters ! and ! are tuned through cross-validation.
In the second stage, we test the associations between the trait of interest and imputed gene expression in each tissue. We denote imputed gene expression in the ith tissue as ! = ! •! and test associations via a univariate regression model:
The z-scores for gene-trait associations in the ith tissue can be denoted as
where denotes the SNP-trait z-scores and ! is a diagonal matrix whose jth diagonal element denotes the ratio between the standard deviation of the jth SNP and that of imputed expression in the ith tissue (Methods). When there is no SNP-trait association, follows a multivariate normal distribution (0, ), where is the LD matrix for SNPs. The covariance matrix of = ( ! , ! , … , ! ) ! can be calculated as
Finally, we combine single-tissue gene-trait association results (i.e. ) using a generalized Berk-Jones (GBJ) test, which takes the covariance among single-tissue test statistics (i.e. Σ) into account [29] . Details on the GBJ statistic and p-value calculation are discussed in the Methods section. 
Cross-tissue analysis improves expression imputation accuracy
We first evaluated the accuracy of cross-tissue expression imputation through five-fold cross-validation on the training data. We used an elastic net model (i.e. the model used in PrediXcan [14] ) trained in each tissue separately as the benchmark for prediction; PrediXcan does not leverage cross-tissue information. Cross-tissue imputation achieved higher imputation accuracy in all 44 tissues (Figure 2A) . On average, imputation accuracy was improved by 38.6% across tissues ( Figure 2B) .
The improvement was particularly high in tissues with low sample sizes in GTEx (N<150; 47.4% improvement). We further calculated the proportion of genes with increased imputation accuracy. Substantially more genes showed improved imputation performance in all 44 tissues ( Supplementary Table 1 ). Using a false discovery rate (FDR) cutoff of 0.05 as the significance threshold, our cross-tissue method achieved 120% more significantly predicted genes across tissues. Among tissues with low sample sizes, the improvement percentage rose even further to 175% ( Figure 2C ).
Next, we performed external validation using an independent dataset. We used our imputation model for whole blood in GTEx to predict gene expression levels in GEUVADIS LCLs (Methods; [30] ). The imputation accuracy quantified as R 2 showed substantial departure from the expected distribution under the null (i.e. expression
and SNPs are independent), which demonstrates the generalizability of cross-tissue imputation (Supplementary Figure 1) . Compared to single-tissue elastic net, cross-tissue imputation achieved significantly higher prediction accuracy across genes (p=3.43e-7; Kolmogorov-Smirnov test), which is consistent with our findings from cross-validation. Two examples of well-predicted genes are illustrated in 
Multi-tissue association test provides statistically powerful inference results
Another key advancement in the UTMOST framework is a novel gene-level association test that combines statistical evidence across multiple tissues. We performed simulation studies using samples from the Genetic Epidemiology Research Study on Adult Health and Aging (GERA; N=12,637) to assess the association test's type-I error rate and statistical power in a variety of settings (Methods). We did not observe inflation in type-I error rate in two different simulation studies ( Supplementary Tables 2-3) . We observed substantial improvement in statistical power of the multi-tissue joint test when gene expression in multiple tissues were causally related to the trait (Figure 3) . When the trait was determined by expression in only one tissue, statistical power of the joint test was comparable to a single-tissue test in the causal tissue. Compared to the naïve test that combines results across tissues while applying an additional Bonferroni correction, our joint test was consistently more powerful (improvement ranged from 17.3% to 24.1%). 
UTMOST identifies more associations in biologically relevant tissues for complex traits
To evaluate the performance of single-tissue association test based on cross-tissue expression imputation, we applied UTMOST to summary statistics from 50 GWAS (N total ≈4.5 million; Supplementary Table 4 ) and compared the results with those of PrediXcan [14] and TWAS [15] . To identify tissue types that are biologically relevant to these complex traits, we applied LD score regression [31] to these datasets and partitioned heritability by tissue-specific functional genome predicted by
GenoSkyline-Plus annotations [32] . Tissue-trait relevance was ranked based on paired Wilcoxon rank test) and 188% improvement compared to TWAS (p=7.39e-8).
Such improvement was consistently observed across traits ( Supplementary Table 5 ).
On the contrary, among other tissues, UTMOST identified similar number of genes and showed no significant difference compared with PrediXcan (p=0.52). Comparing tissues that were most and least enriched for trait heritability, UTMOST identified significantly more associations in tissues strongly enriched for trait heritability than in tissues with the least enrichment (p=0.016) while the contrast was not significant based on PrediXcan (p=0.192) or TWAS (p=0.085). Finally, we applied the cross-tissue joint test to these traits and compared the number of significant genes We applied UTMOST to the meta-analysis summary data of LDL cholesterol from the Global Lipids Genetics Consortium (N=173,082) [33] . Results based on four different analytical strategies, i.e. single-tissue test using liver tissue in GTEx (N=97), single-tissue test using liver eQTLs from STARNET (N=522; [34] ), cross-tissue joint test combining 44 GTEx tissues, and cross-tissue joint test combining 44 GTEx tissues and the liver eQTLs from STARNET, were compared. We identified 57, 58, 185, and 203 significant genes in the four sets of analysis, respectively ( Figure 5A ). Among the identified genes in cross-tissue joint test of 44 GTEx tissues and STARNET-liver, SORT1 had the most significant association (p=3.4e-15). SORT1 is known to causally mediate LDL cholesterol levels, even though the GWAS association signal at this locus is clustered around the CELSR2 gene [35, 36] . Of note, SORT1 is not present in single tissue test with GTEx-liver due to its poor imputation quality (FDR > 0.05). In addition, its associations with LDL-C were not significant in tissues where the imputation was accurate (association p-values ranging from 0.01 in heart atrial appendage to 0.23 in tibial artery). As a result, UTMOST did not identify a strong association between SORT1 and LDL-C even after combining results from 44
GTEx tissues. However, through integrating single-tissue associations in a large external liver dataset (STARNET), we successfully recovered the association of SORT1, which was the most significant at this locus and in the genome (Figure 5B) .
These results suggest that integrative analysis of transciptomic data from multiple tissues can effectively increase statistical power in gene-level association mapping.
Further, UTMOST is a flexible framework and is not limited to GTEx tissues only.
Integrating relevant external QTL studies via UTMOST may further improve downstream association analysis.
UTMOST identifies novel risk genes for Alzheimer's disease
Finally, to demonstrate UTMOST's effectiveness in real association studies, we performed a multi-stage gene-level association study for late-onset Alzheimer's disease (LOAD). In the discovery stage, we applied UTMOST to the stage-I GWAS summary statistics from the International Genomics of Alzheimer's Project (IGAP;
N=54,162; [37] ). Multiple recent studies have suggested that functional regions in the genome in liver and myeloid cells are strongly enriched for LOAD heritability [32, 38, 39] . It has also been suggested that alternative splicing may be a mechanism for many risk loci of LOAD [40] . Therefore, in addition to 44 tissues from GTEx, we also incorporated liver eQTLs from STARNET and both eQTL and sQTL data in three immune cell types (i.e. CD14+ monocytes, CD16+ neutrophils, and naive CD4+ T cells) from the BLUEPRINT consortium in our analysis (Methods). Single-tissue association tests were performed and then combined using the GBJ test. In total, our cross-tissue analysis identified 68 genome-wide significant genes in the discovery stage ( Supplementary Table 6 and Supplementary Figure 3) .
We tried to replicate our findings in two independent datasets, i.e. GWAS summary statistics based on samples in the Alzheimer's Disease Genetics Consortium (ADGC) that were not used in the IGAP stage-I analysis (N=7,050), and summary statistics from the genome-wide association study by proxy (GWAX; N=114,564; [41] 6 ). These 69 genes were significantly enriched for seven gene ontology terms ( Supplementary Table 8) , with "very-low-density lipoprotein particle" being the most significant (adjusted p=5.8e-3). . Among these loci, AGFG2 rather than ZCWPW1, the previously-suggested index gene at this locus [37] , was significant in the meta-analysis (p=7.19e-7). Similarly, BIN1 was not statistically significant in our analysis. But LIMS2, a gene 500 kb upstream of BIN1, was significantly associated (p=9.43e-12). SNPs in the 3'UTR of LIMS2 have been previously suggested to associate with cognitive decline [48] . GWAS index genes for the rest of the loci were all statistically significant in our analysis.
Further, new associations at known risk loci provide novel insights into LOAD etiology.
We identified a novel gene IL10 for LOAD risk (p=1.77e-7). IL10 is 700 kb upstream of CR1, a well-replicated LOAD risk gene that is also significant in our analysis (p=3.71e-7) [37, 47, 49] . Although some SNPs near the promoter region of IL10 were moderately associated with LOAD in all three datasets (Supplementary Figure 4) , the IL10-LOAD association was mostly driven by SNPs near CR1 ( Supplementary   Table 9 ). IL10 is associated with multiple immune diseases [50] [51] [52] [53] and is known to encode an anti-inflammatory cytokine that has therapeutic potential to improve neurodegeneration [54, 55] . Its protein product is also known to physically interact with Tau protein [56] . CLU is another well-replicated risk gene for LOAD. Two independent association peaks at this locus, one at CLU and the other at PTK2B, have previously been identified in GWAS (Supplementary Figure 5 ) [37, 47] . In our analysis, in addition to CLU (p=1.66e-10), we identified two more significant genes at this locus, i.e. ADRA1A (p=1.29e-9) and EXTL3 (p=5.08e-12). PTK2B showed marginal association (1.72e-4) with LOAD but did not reach genome-wide significance. Interestingly, EXTL3 expression is predicted by a SNP in the LOAD association peak at CLU while ADRA1A is regulated by SNPs at both CLU and PTK2B ( Supplementary Table 10 ). ADRA1A has been implicated in gene-gene interaction analysis for LOAD [57] . Its protein product physically interacts with amyloid precursor protein (APP) [56] and an α 1 -adrenoceptor antagonist has been shown to prevent memory deficits in APP23 transgenic mice [58] . EXTL3 is a putative membrane receptor for regenerating islet-derived 1α (Reg-1α), whose overexpression and involvement in the early stages of Alzheimer's disease has been reported [59] .
Further, the effect of Reg-1α on neurite outgrowth is mediated through EXTL3. Our results provide additional evidence that IL10, ADRA1A, and EXTL3 may be involved in LOAD etiology.
Finally, we identified five novel loci for LOAD ( Supplementary Tables 6-7) , each represented by one significant gene: NICN1 (p=2.23e-7), RAB43 (p=1.98e-6), VKORC1 (p=3.53e-9), HPR (p=3.02e-7), and PARD6G (p=3.60e-11). The Rab
GTPases are central regulators of intracellular membrane trafficking [60] . Although RAB43 has not been previously identified in LOAD GWAS, USP6NL, the gene that encodes a GTPase-activating protein for RAB43, has been identified to associate with LOAD in two recent studies [41, 46] . USP6NL also showed suggestive association with LOAD in the discovery stage of our analysis (p=0.004). However, the associations at RAB43 and USP6NL were not strongly supported by ADGC or GWAX datasets. Further, the RAB43-LOAD association was driven by SNPs near RPN1, a gene 400 kb downstream of RAB43 (Supplementary Figure 6 and Supplementary   Table 11 ). This locus is associated with a variety of blood cell traits including monocyte count [61, 62] . VKORC1 is a critical gene in vitamin K metabolism and is the target of warfarin [63] , a commonly prescribed anticoagulant. It is known that the APOE ε4 allele affects the efficacy of warfarin [64] . HPR has been identified to strongly associate with multiple lipid traits [65] and interact with APOE [56] . NICN1 is known to associate with inflammatory bowel disease [66] and cognitive function [67] .
These results provide potential target genes for functional validations in the future.
Discussion
In this paper, we introduced UTMOST, a principled framework to perform cross-tissue expression imputation and gene-level association testing. Compared to single-tissue methods, cross-tissue imputation substantially improves imputation accuracy in all tissues in the training data. Through analysis of 50 complex traits, we demonstrated that single-tissue association analysis based on cross-tissue expression imputation could identify more associations in tissues relevant to trait etiology. In addition, we proposed a unified test that combines evidence of gene-trait association across multiple tissues. We demonstrated through both simulation and analysis of real GWAS data that our cross-tissue joint test is more powerful than single-tissue analysis, especially when a true association is present in multiple tissues. Further, UTMOST is capable of integrating external eQTL data to further enhance performance and can be expanded to incorporate any linearly imputed molecular phenotypes such as splicing or methylation QTL. Finally, we note that UTMOST only requires GWAS summary statistics as input.
To demonstrate the performance of UTMOST on real GWAS data, we performed a cross-tissue transcriptome-wide association meta-analysis for LOAD using three independent datasets. In total, we identified 69 genome-wide significant genes from 15 loci. A few novel genes are several hundred kb from known LOAD-associated SNPs and have not been previously identified as candidate risk genes for LOAD. In addition, we also identified five novel risk loci. Our results showcased UTMOST's effectiveness in interpreting GWAS associations and identifying novel genetic loci.
More importantly, these findings provide insights into LOAD etiology and may guide future functional validations.
Despite the advancements, researchers need to be cautious when interpreting findings of UTMOST analyses. First, gene-level associations identified in UTMOST do not imply causality. It has been recently discussed that correlations among the imputed expression of multiple genes at the same locus may lead to apparent associations at non-causal genes [20] , which is comparable to LD's impact on SNP-level associations in GWAS. Fine-mapping of causal genes in both single-tissue and cross-tissue analyses remains challenging. Second, we emphasize one of the principles in hypothesis testing -one should not conclude the null hypothesis when an association is not statistically significant. UTMOST is a general framework that involves many analytical steps, and technical issues might mask true gene-trait associations. For example, SPI1 from the CELF1 locus has been causally linked to LOAD risk [39] . We identified multiple significant associations at this locus but SPI1
was not a significant gene in our analysis. Possible reasons for this include insufficient imputation quality based on the current model, non-availability of causal tissue in the training data, key eQTL missing from the GWAS summary statistics, causal mechanism (e.g. alternative splicing) not well-represented in our analysis, or insufficient sample sizes. In practice, these issues need to be carefully investigated before ruling out any candidate gene.
Nevertheless, UTMOST is a novel, powerful, and flexible framework to perform gene-level association analysis. It integrates biologically-informed weights with GWAS summary statistics via modern statistical techniques. Interpreted with caution, its findings may provide insights into disease and trait etiology, motivate downstream functional validation efforts, and eventually benefit the development of novel therapeutics. It is also exciting that statistical and computational methodology in this field evolves at a fast pace. Several methods on mediation analysis and functional gene fine-mapping in the context of transcriptome-wide association study have been proposed recently [68, 69] . It has also been shown that data-adaptive SNP weights could effectively improve statistical power at the cost of clear interpretation of associations [70] . Extension of these methods into multi-tissue analysis is an interesting possible future direction. As high-throughput data continue to be generated for more individuals, cell types, and molecular phenotypes, UTMOST promises to show even better performance and provide greater insights for complex disease genetics in the future.
Methods
Penalized regression model for cross-tissue expression imputation
Given a gene, we use genotype information to predict its covariate-adjusted expression levels in tissues. We use SNPs between 1 Mb upstream of the transcription start site and 1 Mb downstream of the transcription end site of the given gene as predictor variables in the model. This is denoted as an × matrix where is the total number of individuals and denotes the number of SNPs.
Throughout the paper, we assume each column of to be centered but not standardized. Of note, expression data may not be available for all individuals since only a subset of tissues were collected from each individual. For the th tissue, we use ! to denote its sample size. We further use an ! -dimensional vector ! to denote the observed expression data in the th tissue, and use an ! × matrix ! to denote the genotype information for the subset of individuals. Then, cross-tissue gene expression imputation can be formulated as the following regression problem.
Here, the × matrix summarizes SNPs' effects on the given gene with its th column •! denoting the effect sizes of SNPs in the th tissue and the th row !• denoting the effect sizes of the th SNP in all tissues. To effectively select biologically relevant and statistically predictive SNPs, accurately estimate their effects across tissues, and address technical issues including shared samples and incomplete data, we propose the following penalized least-squares estimator for genetic effects matrix :
Here, . ! and . ! denote the ! and ! norms, respectively (i.e.
). The first term in the loss function is the standard least-squares error. We use the ! penalty to select predictive variables and impose shrinkage in effect size estimation. The penalty on each tissue is set adaptively based on the sample sizes, which reflects the idea that models for tissues with a larger sample size are more robust to overfitting and therefore are penalized less. To integrate information across multiple tissues, we introduced the third term -a group-lasso penalty on the effect sizes of one SNP [71] . By imposing this joint penalty across tissues, we could effectively eliminate non-eQTL SNPs especially in tissues with small sample sizes and keep strong cross-tissue effects. Of note, the bias-variance tradeoff needs to be taken into consideration to achieve better prediction accuracy. Given the large number of tissues and the limited yet imbalanced sample size for each tissue in GTEx data, we chose to apply a cross-tissue penalty instead of explicitly modeling tissue-tissue correlations to avoid overfitting. Tuning parameters λ 1 and λ 2 control the within-tissue and cross-tissue sparsity, respectively.
They are selected through cross-validation.
Optimization
To minimize the objective function, we developed a novel coordinate descent approach that extended the optimization procedure in [72] to deal with incomplete data in the outcome matrix. In each iteration, we update a row of . When (!!)• (i.e. all the rows except for the th) have been updated, the procedure is equivalent to
jth column and the matrix excluding the jth column of ! ( ! × ), respectively. For a specific ∈ (1, … , ), when !" > 0, its partial derivative is
And the minimum of !" ; !(!!) with !" > 0 and !(!!) fixed is
Similarly, when !" ≤ 0, we have
The minimum of !" ; !(!!) with !" ≤ 0 and !(!!) fixed is
< 0 for !" < 0, then !",!"# ≥ 0 and
≥ 0 for !" ≥ 0, then !",!"# ≤ 0 and
which is the same formula as in the previous case. Denoting the minimum of !• as !•,!"# ∶= !!,!"# , … , !",!"# , we have shown that if such a minimum exists, it should satisfy:
We keep training the model until convergence in or the mean squared error starts increasing in the validation set. Numerical experiments demonstrated that the proposed procedure provided reasonable approximation in each iteration and resulted in robust prediction models (Figure 2 and Supplementary Table 1 ).
Model training and evaluation
We trained our cross-tissue gene expression imputation model using genotype and normalized gene expression data from 44 tissues in the GTEx project (version V6p) [3] . Sample sizes for different tissues ranged from 70 (uterus) to 361 (skeletal muscle).
SNPs with ambiguous alleles or minor allele frequency (MAF) < 0.01 were removed.
Normalized gene expressions were further adjusted to remove potential confounding effects from sex, sequencing platform, top three principal components of genotype data, and top probabilistic estimation of expression residuals (PEER) factors [73] . As previously recommended [17] [30] .
Gene-level association test
We combined GWAS summary statistics with SNP effects estimated in the cross-tissue imputation model (i.e. ) to quantify gene-trait associations in each tissue. For a given gene, we modeled its imputed expression in the th tissue (i.e. ! = ! •! ) and the phenotype using a linear model
Then, the association statistic for effect size in the th tissue (i.e. ! ) on the trait of interest is
where ! denotes the point estimate for effect size and ( ! ) denotes its standard error. From the linear model, we have
where ! is an × diagonal matrix with the th term equal to
, where ! is the standard deviation of the th SNP, and ! is the standard deviation of imputed gene expression in the th tissue. These parameters could be estimated using a reference panel. denotes the SNP-level effect size estimates acquired from GWAS summary statistics. Regarding the standard error of ! , we have
Here, ! denotes the standard deviation of phenotype and !"#$ is the sample size in GWAS. The approximation ( ! ) ≈ ! ! is based on the empirical observation that each gene only explains a very small proportion of phenotypic variability [74] . The same argument can be extended to association statistics at the SNP level. For the th SNP in the model, we have
Therefore, SNP-level z-scores can be denoted as
In matrix form, this is
Combining the derivations above, we can denote the gene-level z-score as
Under the null hypothesis (i.e. no SNP-trait association), follows a multivariate normal distribution ~(0, ), where is the LD matrix for SNPs and could be estimated using an external reference panel. Denoting the cross-tissue gene-trait z-scores as = ( ! , ! , … , ! ) ! , the covariance matrix of could be calculated as
In order to combine gene-trait associations across multiple tissues, we applied the generalized Berk-Jones (GBJ) test with single-tissue association statistics and their covariance matrix Σ as inputs. This approach provides powerful inference results while explicitly taking the correlation among single-tissue test statistics into account even under a sparse alternative (i.e. biologically meaningful associations are only present in a small number tissues) [29] . The GBJ test statistic can be calculated
where | | (!) denotes the th order statistic of the absolute value of gene-trait z-scores in an increasing order;
denotes the number of gene-trait z-scores with absolute value greater than a threshold ; ! denotes the corresponding value of that maximizes the probability of event | | (!!!!!) = ;
and Φ = 1 − Φ is the survival function of the standard normal distribution. The GBJ test statistic can be interpreted as the maximum of a series of one-sided likelihood ratio test statistics on the mean of , where the denominator denotes the maximum likelihood when no gene-trait association exists in any tissue (all z-scores have zero mean) and the numerator denotes the unconstrained maximum likelihood.
Of note, calculating the exact distribution of is difficult when z-scores are correlated. As previously suggested, we calculate by approximating the distribution of with an extended beta-binomial (EBB) distribution. As a maximum-based global statistic, the p-value of GBJ test could be written as
where 0 ≤ ! ≤ ! ≤ ⋯ ≤ ! are 'boundary points' derived from inversion of the test statistic, which depends on , and Σ. The last quantity in the equation can be calculated recursively with the EBB approximation [29] .
Simulation settings
Genotype data from 12,547 individuals in the GERA dataset (dbGaP accession: phs000674), including 7,432 type-2 diabetes cases (phenotypic information not used) and 5,205 healthy controls, were used in the simulation studies. We removed SNPs with missing rate above 0.01 and individuals with genetic relatedness coefficients above 0.05. The genotype data were imputed to the 1000 Genomes Project Phase 1v3 European samples using the Michigan Imputation Server [75] . After imputation, we further removed SNPs with MAF < 0.05. After quality control, 5,932,546 SNPs remained in the dataset.
We performed two different simulation studies to evaluate the type-I error rate of our cross-tissue association test. First, we directly simulated quantitative traits from a standard normal distribution independent from the genotype data, and then performed single-tissue association tests for 44 tissues in GTEx and GBJ cross-tissue association test for all genes using the simulated data. In the second setting, we simulated genetically-regulated expression components and then simulated the GWAS trait based on gene expression values. For each gene, we simulated its expression in three tissues, namely skeletal muscle (N=361), skin from sun-exposed lower leg (N=302), and whole blood (N=338). Within the th tissue, the cis-component of gene expression was generated as ! = ! •! . We used real effect sizes •! estimated in our joint imputation model so that the genetic architecture of gene expression was preserved in the simulations. Next, the quantitative trait value was simulated as = ! ! + ! ! + ! ! + , where ! is the effect of gene expression on the trait in the th tissue. To evaluate type-I error, we set ! = ! = ! = 0, i.e. none of the three tissues are relevant to the trait.
To simulate data under the alternative hypothesis, we fixed the total variance explained by ! , ! , and ! (i.e. ! ) to be 0.01, and varied ! to simulate different levels of tissue specificity of the trait. We generated traits using the following three settings:
Setting 1. ! = 1, ! = ! = 0. Only the first tissue contributes to the disease, the other two tissues are not relevant. Single-tissue and cross-tissue gene-trait associations were then estimated using the UTMOST framework. We repeated the whole procedure on 200 randomly selected genes. For each gene, we further replicated 5 times. Statistical power is calculated as the proportion of test p-values reaching the significance threshold, i.e. 0.05/15000 for both single-tissue and cross-tissue tests and 0.05/45000 for single tissue tests while accounting for the number of tissues.
GWAS data analysis
We applied UTMOST to GWAS summary statistics for 50 complex diseases and traits.
Details of these 50 studies are summarized in Supplementary Table 4 ADGC phase 2 summary statistics were generated by first analyzing individual datasets using logistic regression adjusting for age, sex and the first three principal components in the program SNPTest v2 [76] . Meta-analysis of the individual dataset results was then performed using the inverse-variance weighted approach in METAL [77] .
In the UTMOST analytical framework, multiple parameters need to be estimated using an external reference panel (e.g. LD). We used samples with European ancestry from the 1000 Genomes Project for this estimation [78] . When performing cross-tissue association tests, we combined single-tissue statistics from tissues that passed FDR < 0.05 criteria to reduce noise in the analysis. Genome-wide significance was defined as 3.3e-6 (i.e. Bonferroni correction based on 15,120 genes that passed the quality control steps). For heritability enrichment analysis, we applied LDSC to 27
GenoSkyline-Plus tissue-specific annotations that have matched tissue types in GTEx (Supplementary Table 12 ). The 53 LDSC baseline annotations were also included in the model as previously recommended [31] . The most and least relevant tissues were selected based on the enrichment test p-values. Gene ontology enrichment analysis was performed using DAVID [79] . Protein-protein interaction information was acquired from AlzData website (http://alzdata.org/index.html) [56] . Locus plots for SNP-level GWAS associations were generated using LocusZoom [80] . Manhattan plots were generated using the qqman package in R [81] .
Additional QTL data
Imputation model for liver tissue in the STARNET study (N=522) was downloaded from (https://github.com/Wainberg/Vulnerabilities_of_TWAS). Predictor effects were trained using an elastic-net model with variants within 500kb range of the transcription-starting site. Details on the quality control procedure has been previously reported [20] . We have also collected additional eQTL and sQTL data for three immune cell types (CD14+ monocytes, CD16+ neutrophils, and naive CD4+ T cells;
169-194 samples per tissue) from the BLUEPRINT consortium (ftp://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint Epivar/qtl as/). eQTLs with FDR < 0.01 and sQTLs with FDR < 0.05 were used in the gene-level association analysis for LOAD.
Software availability
UTMOST software is freely available at https://github.com/Joker-Jerome/UTMOST.
